Business Context and Reporting Period
Company: Trinity Biotech PLC
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: December 2024 (Filed December 27, 2024)
Principal Executive Office: IDA Business Park Bray, County Wicklow, Ireland
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is a regulatory update regarding a securities offering.
Material Changes
The filing discloses an amendment to an existing At the Market Offering Agreement:
- Agreement Date: July 12, 2024 (Original agreement with Craig-Hallum Capital Group LLC).
- Amendment Date: December 16, 2024 (Prospectus Supplement filed).
- Change: The Company may sell up to an additional $2,306,000 of American Depositary Shares (ADSs).
- Share Structure: Each ADS represents 20 of the Company's A Ordinary Shares (par value $0.0109 per share).
- Agent: Craig-Hallum Capital Group LLC acting as sales agent.
Guidance, Outlook, and Risks
The filing does not provide management commentary, financial guidance, or specific risk factors beyond the standard disclosure of the securities offering. The document incorporates by reference into Registration Statements on Form F-3 (File No. 333-280391).
Investor Verification Checklist
- Verify the total remaining capacity under the At the Market Offering Agreement after this $2,306,000 increase.
- Review the full Prospectus Supplement filed on December 16, 2024, for terms regarding sales commissions and pricing.
- Confirm the current share count and dilution impact of the potential ADS issuance.
- Check the Form F-3 (File No. 333-280391) for broader context on the Company's capital raising strategy.